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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S303literature, free radical degradation is an important factor of HA degra-
dation in the joint and is a key factor of the OA (free radicals is asso-
ciated with chondrocyte death and cartilage destruction).
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Purpose: Synovial ﬂuid is a joint lubricant and plays an important role in
cartilage deformation caused by mechanical load. The main component
of synovial ﬂuid is hyaluronic acid with an approximate concentration of
2,5mg/ml and the averagemolecularweight of 3-5MDa in healthy joints.
It is known, that in osteoarthritis the concentration and the average
molecular weight of HA in synovial ﬂuid are signiﬁcantly reduced. This
has a negative effect on the viscoelasticity of the synovial ﬂuid, which
leads to signiﬁcant decrease of the mechanical protection of the articular
system. Also, the articular cartilage function deteriorates. It is also known
that preparations for medical treatment with smaller average molecular
weight have not sufﬁcient viscoelastic properties and undergo biodeg-
radation too quickly. In our previous work we designed a new HAtyramine derivative containing an alkyl‑based linker for the preparation
of non-cytotoxic and biocompatible hydrogel‑based materials with
enhanced mechanical properties. In this work this HA derivative was
further optimized to become a material with suitable properties for
synovial ﬂuid viscosupplementation. For this purpose, partially cross-
linked solutions of this HA derivate were tested.
Methods: In this study partially crosslinked solutions on the basis of the
HAderivatementioned abovewere designed.We studied the inﬂuence of
crosslinked density, HA derivativemolecularweight and concentration of
these solutions in order to optimize the viscoelasticity and to reach the
appropriate properties correspondingwith synovialﬂuid. The viscoelastic
propertiesweremeasured by dynamicmechanical analysis in a frequency
sweep oscillation mode (frequency 0,1-10 Hz at 0,5% strain) and by
determination of storage modulus G0, loss modulus G00 and loss angle d.
Results:
Fig.1:Representative resultsobtainedfromDynamicmechanicalanalysis ina frequency
sweep oscillationmode (frequency 0,1-10 Hz at 0,5% strain) of selected samples
Conclusions: The results obtained so far showed that we can design
and prepare HA‑based materials with suitable properties for synovial
ﬂuid viscosupplementation. Thanks to the partial crosslinking of the HA
solutions we are also able to design materials with enhanced visco-
elastic properties and prolonged biostability compared to HA‑based
treatment preparations with insufﬁcient molecular weight.
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Purpose: The purpose of this study is to develop the nanoparticles that
i) can be injected intra-articularly ii) target to cartilage due to an
opposite charge difference with the extracellular cartilaginous matrix
and iii) due to their small size can penetrate into the cartilage. In this
way retention time in the joint can be prolonged. By releasing disease
modifying OA drugs (DMOAD) in the vicinity of chondrocytes such
materials may be beneﬁcial for restoring cartilage tissue homeostasis.
Here we demonstrate the generation of drug-containing nanoparticles
for intra-articular joint therapy.
Methods: We have prepared nanoparticles of biodegradable poly
ethylene glycol- poly lactic acid PEG-PLA co-block polymers. The
hydrophilic PEG and hydrophobic PLA ends of this polymer make it
possible to generate micelles that contain drugs. The polymers are
functionalized with UV-sensitive acrylate groups that can be stabilized
by UV-crosslinking. These drug containing nanoparticles will be used
for intra-articular joint injection and release of DMOADs. We have also
established co-culture systems in vitro using MSCs and chondrocytes
where the effect of these molecules and nanocarriers can be tested.
Results: Micelle type nanoparticles using PEG-PLA co-block polymers
were prepared. The obtained dexamethasone loaded nanoparticles had
diameters of 20-80 nm. These nanoparticles are photo-crosslinked at
their hydrophobic cores which provides stability to the structure and
resulted in a slight decrease in average particle size . Dexamethasone
was successfully encapsulated in these nanoparticles. The current
release proﬁles show initial burst release in the ﬁrst 8 hours followed by
a sustained release over at least 3 days.
